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Evaluation of Canine Pancreas-Specific Lipase Activity, Lipase
Activity, and Trypsin-Like Immunoreactivity in an Experimental
Model of Acute Kidney Injury in Dogs
S.E. Hulsebosch, C.A. Palm, G. Segev, L.D. Cowgill, P.H. Kass, and S.L. Marks
Background: Diagnosis of pancreatitis in dogs is complicated by extrapancreatic disorders that can alter the results of lab-
oratory tests. Extrapancreatic disorders can also affect the diagnosis of exocrine pancreatic insufficiency (EPI). The effects of
acute kidney injury (AKI) on pancreas-specific lipase activity (Spec cPL Test), serum lipase activity and trypsin-like
immunoreactivity (TLI) in dogs have not been evaluated.
Hypothesis/Objectives: Serum Spec cPL, lipase activity, and TLI concentrations will increase secondary to decreased kid-
ney function.
Animals: Five purpose-bred dogs.
Methods: Experimental prospective study. Gentamicin was used to induce AKI in 5 purpose-bred dogs. Serum samples
were collected for measurement of creatinine, Spec cPL, lipase activity and TLI over 60 days, during both induction of, and
recovery from, AKI.
Results: All dogs developed and recovered from AKI. Six of 52 (12%) serum Spec cPL concentrations were increased (2
in the equivocal zone and 4 consistent with pancreatitis) in 2 of 5 (40%) dogs. Two of 51 (4%) serum lipase activity values
were increased in 2 of 5 dogs. Serum TLI was increased above the reference range in 17 of 50 (34%) samples in 3 of 5 dogs.
For all biomarkers, there was no consistent correlation with increases in serum creatinine concentration.
Conclusions and Clinical Importance: Decreased renal excretion during experimental AKI did not cause consistent and
correlated increases in serum Spec cPL, lipase activity, or TLI in this cohort of dogs.
Key words: Creatinine; Exocrine pancreatic insufficiency; Pancreatitis; Spec cPL.
Acute pancreatitis occurs commonly in dogs.Affected dogs can present with a wide spectrum of
clinical signs and physical examination findings, includ-
ing lethargy, anorexia, vomiting, diarrhea, and abdomi-
nal pain.1 The definitive antemortem diagnosis of acute
pancreatitis remains challenging, despite the availability
of improved serologic testing and abdominal imaging
modalities.2–5 Pancreatic histopathology is the gold
standard for definitive diagnosis of pancreatitis; how-
ever, procurement of pancreatic tissue is invasive,
expensive, and impractical in a debilitated dog. Addi-
tionally, multifocal disease within the pancreas and the
lack of a uniformly accepted classification scheme for pancreatic histopathology in veterinary medicine further
limits the utility of histopathology for diagnosis of pan-
creatitis.6
In the absence of histopathology, the history, physical
examination, abdominal ultrasound, and serum bio-
chemical testing remain the current mainstays for diag-
nosis of pancreatitis in veterinary medicine.1
Historically, serum lipase activity, amylase activity, and
trypsin-like immunoreactivity (TLI) have been used to
diagnose pancreatitis, and TLI can be included in a
comprehensive gastrointestinal panel with canine pan-
creas-specific lipase concentration (Spec cPL Test) to
help evaluate exocrine pancreatic function. These
biomarkers can be affected by extrapancreatic diseases,
which can lead to decreased specificity.7 One of the
speculated causes for this decreased specificity is the
effect of renal dysfunction, but this has not been fully
evaluated in veterinary medicine. The Spec cPL Test is
reported to be the most sensitive (65–94%) and specific
(66–100%) noninvasive biomarker currently available
for the diagnosis of pancreatitis in dogs2,4,8–11; 1 study
reported a sensitivity of 21% with mild pancreatitis.9
Acute kidney injury (AKI) and pancreatitis can lead
to similar clinical signs. In addition, these 2 conditions
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are common comorbidities, as AKI is a well-documen-
ted cause of pancreatitis via ischemia and hypovolemia,
and pancreatitis can lead to AKI via hypovolemia and
cytokine-induced ischemia and inflammation.12,13 As
with other serological biomarkers of pancreatitis, it is
plausible that decreased glomerular filtration rate
(GFR), as seen with AKI, could result in Spec cPL
increase secondary to decreased renal clearance, in the
absence of pancreatitis. The influence of altered renal
function on the serum concentration of canine pancre-
atic lipase immunoreactivity (cPLI), a test similar to
Spec cPL, was evaluated in 17 dogs with experimentally
induced chronic kidney disease (CKD).14 Results
showed a positive correlation between serum creatinine
and cPLI; however, the clinical utility of the test was
not affected by CKD when tested at a single time point
in these dogs.14 There has been no critical evaluation of
Spec cPL, serum lipase activity or TLI in dogs with
AKI, and the sensitivity and specificity of these tests in
affected dogs is therefore unknown.
The aim of this study was to evaluate serum Spec
cPL concentrations, lipase activity, and TLI in dogs
during induction of, and recovery from, AKI. It was
hypothesized that experimentally induced AKI would
lead to increases in serum Spec cPL concentrations,




Six 2-year-old female intact, purpose-bred hound dogs were
screened for inclusion by physical examination, complete blood
count, serum chemistry panel, urinalysis, and bacterial urine cul-
ture and sensitivity. This prospective study was approved by the
University of California-Davis Institutional Animal Care and Use
Committee (IACUC).
Induction of AKI and Monitoring
Acute kidney injury was induced by gentamicin administration
at 8 mg/kg subcutaneously q8 hours. If AKI was not demonstrated
after 7 days, the gentamicin dose was increased to 10 mg/kg
subcutaneously q8 hours.15,16 This dose was maintained until
induction of AKI, which was defined by a 50% increase in
creatinine above the baseline (day 0) value.17–19
During the course of the study, dogs were monitored for devel-
opment of any abnormal clinical signs, including hypodipsia and
hyporexia. For any dog that developed hypodipsia, based on the
subjective assessment of the attending clinician, supplemental sub-
cutaneous fluid administration was instituted to prevent dehydra-
tion, hypovolemia, or both. This was done in an attempt to
maintain adequate renal perfusion and facilitate recovery from
AKI.
Blood and Urine Collection
Blood was collected via jugular or lateral saphenous venipunc-
ture from each dog for evaluation of serum creatinine and BUN
concentrations, and urine was collected by cystocentesis or free
catch for measurement of USG at the following time points: day 0
(defined as the day before gentamicin administration), twice daily
(at 8 am and 4 pm) during induction of AKI, once daily for 4–
6 days after AKI was documented, and then on days 26, 28, 31,
35, 39, 46, and 60. After collection, blood and urine samples were
immediately placed on ice before centrifugation in a refrigerated
centrifuge. Serum creatinine, BUN, and USG were analyzed the
day of collection at the VMTH laboratory.a Remaining serum and
urine samples were stored at 80°C and select serum samples were
subsequently submitted for batched biomarker analysis.
Pancreatic Biomarker Analysis
In order to analyze biomarkers during both AKI induction and
recovery, creatinine was used to estimate changes in GFR, and
subsequently, renal excretion. Time points for biomarker analysis
were selected based on changes in serum creatinine concentration
compared to baseline and compared to maximum serum creatinine
concentration.20 Stored serum samples from each dog were sub-
mitted frozen on dry ice to a commercial laboratoryb for batched
measurements of serum Spec cPL, lipase activity, and TLI at the
following time points: (1) baseline serum creatinine concentration
before gentamicin administration (day 0), (2) the first documented
increase in serum creatinine concentration above 25%, 50%, 75%,
and 100% of the baseline creatinine concentration, (3) the maxi-
mum creatinine concentration, (4) during the recovery phase of
AKI, as reflected by the first documented decrease in serum crea-
tinine of 25%, 50%, and 75% below the maximum creatinine con-
centration, (5) at the end of the study (day 60). After preliminary
Spec cPL results were analyzed, additional serum samples were
then submitted for Spec cPL, lipase activity, and TLI analysis in
dogs with Spec cPL increases, in order to further elucidate the
relationship between these biomarkers and creatinine.
Spec cPL was assayed by a monoclonal antibody sandwich
ELISA as previously described.5 According to the manufacturer,
the assay has 3 ranges of interpretation: 0–200 lg/L is within the
normal reference range; 201–399 lg/L is an equivocal zone; and
≥400 lg/L is consistent with pancreatitis. Serum lipase activity
(reference range 138–755 U/L) was analyzed using a 1,2-diglycer-
ide enzymatic/colorimetric assay,c and TLI (reference range 5–
35 lg/L) was analyzed using a chemiluminescence immunoassay.d
Statistical Analysis
Linear regressions between creatinine concentration and
biomarkers (ie, Spec cPL, lipase activity and TLI) were evaluated
both individually for each dog, and as a group analysis (all dogs)
with Student’s t-tests to determine if the regression and correlation
coefficients (r) were significantly different from 0. For group analy-
sis, linear regressions with robust variance estimation to account
for the replicate measurements within individual dogs were simi-
larly used to test if the correlation coefficients were significantly
different from 0. P values <.05 were considered statistically signifi-
cant. Data were analyzed using Stata/IC 13.1 software.e
Results
Baseline Renal Function
One dog was excluded from the study because of the
presence of an E. coli bacterial cystitis, and therefore, 5
dogs were enrolled. Before gentamicin administration,
all 5 dogs had unremarkable biochemistry analyses.
Median baseline creatinine concentration was 1.0 mg/dL
(range 0.7–1.0 mg/dL; reference range 0.8–1.5 mg/dLa)
and median baseline USG was 1.046 (range 1.024–
1.050).
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Induction of Acute Kidney Injury
All dogs developed AKI within 14–20 days (median
14 days) after gentamicin commencement, and all dogs
required the increased gentamicin dose (10 mg/kg sub-
cutaneously q 8 hours). The median serum creatinine
concentration at the peak of the AKI was 4.2 mg/dL
(range 1.4–5.1 mg/dL; reference range 0.8–1.5 mg/dL)
and the mean peak serum creatinine concentration was
3.5  1.67 mg/dL. One dog did not become azotemic,
but did develop AKI with a 100% increase above base-
line creatinine, from 0.7 to 1.4 mg/dL. Serum creatinine
concentrations were higher than the upper limit of the
reference range in 27 of 52 (52%) serum samples. Addi-
tionally, 35 of 52 (67%) serum creatinine concentrations
documented AKI. Median duration to development of
isosthenuria (USG ≤ 1.012) was 12 days (range 7–
13 days).
Dogs weighed a median of 22.3 kg (range 20.0–
22.7 kg) and were administered lactated ringers solution
at approximately 50–100 mL/kg/day (1 L subcuta-
neously q 12–24 hours per dog) when hypodipsia was
noted. Mild hyporexia also occurred when hypodipsia
was present. Fluid administration was indicated only
during the recovery phase of AKI, with a median of 5
(range 1–9) fluid administrations per dog. The start of
the recovery phase was defined when serum creatinine
first decreased after its peak value and occurred at a
median of 23 days (range 21–24 days).
Pancreatic Biomarker Analysis
Based on the above mentioned criteria for sample
selection for biomarker analysis, it was anticipated to
have 10 samples measured per dog; however, sample
overlap (eg, 100% above baseline creatinine also being
the maximum creatinine value) eliminated a total of 7
samples. Therefore, in 3 dogs, 9 samples were initially
evaluated, and in 2 dogs, 8 samples were initially evalu-
ated. In the 2 dogs with increased Spec cPL concentra-
tions noted after initial evaluation, additional serum
samples were submitted, for a total of 12 samples in 1
dog and 14 samples in the other dog. These additional
serum samples were from days 19, 21, 24, and 39 for 1
dog and days 18, 19, 22, 28, and 35 for the other dog.
Baseline Biomarker Results
Before induction of AKI, all dogs had baseline Spec
cPL concentrations within the reference range (0–
200 lg/L) with a median concentration of 51 lg/L
(range 31–108 lg/L) and a mean of 64.8  33.4 lg/L.
Median serum lipase activity at baseline was 338 U/L
(range 220–779 U/L; reference range 138–755) with a
mean of 457  252 U/L. One dog had an increased
serum lipase activity at baseline (779 U/L); however,
the Spec cPL (42 lg/L) and TLI (27.8 lg/L) concentra-
tions were within their respective reference ranges. The
median serum TLI concentration at baseline was
27.4 lg/L (range 22.7–48.5 lg/L; reference range 5–35)
with a mean of 30.3  10.3 lg/L. One dog had an
increased baseline serum TLI concentration (48.5 lg/L);
however, baseline Spec cPL (108 lg/L) and serum lipase
activity (220 U/L) were within the reference ranges for
this dog.
Biomarkers During AKI Induction and Recovery
A total of 52 serum samples from the 5 dogs were
analyzed for Spec cPL concentrations (Fig 1). Spec cPL
was in the equivocal range (201–399 lg/L) in 2 of 52
(4%) samples and was ≥400 lg/L in 4 of 52 (8%) sam-
ples. These increases were documented in 2 of 5 dogs.
For each of these 2 dogs, the increases in Spec cPL con-
centration occurred sequentially, and values before and
after these increases were within the normal reference
range. Only 1 of these 2 dogs had a significant positive
linear correlation between Spec cPL and serum crea-
tinine concentration (r = 0.704, P = .005) (Table 1).
Fig 1. Scatter plot representing creatinine concentrations and Spec cPL concentrations for all 5 dogs. Creatinine reference range (0.8–
1.5 mg/dL). Spec cPL reference range (0–200 lg/L). Spec cPL equivocal range (201–399 lg/L) denoted by shaded box.
194 Hulsebosch et al
The highest documented serum creatinine concentration
for all dogs was 5.1 mg/dL, which was correspondent
with a normal Spec cPL of 178 lg/L. Spec cPL
remained <200 lg/L throughout the study in the other
3 dogs and there was no significant linear correlation
between Spec cPL and serum creatinine in these 3 dogs
(Table 1, Fig 2). When analyzing the data as a group,
there was minimal and nonsignificant correlation
between serum creatinine concentration and Spec cPL
in the 5 dogs (r = 0.235, P = .095) (Fig 1).
Serum lipase activity was increased in 2 of 51 (4%)
samples evaluated (Fig 3). These 2 increases occurred in
2 dogs. In 1 dog, the increased lipase activity was docu-
mented at the baseline measurement when creatinine
concentration was 1.0 mg/dL, and concurrent Spec cPL
(42 lg/L) and TLI (27.8 lg/L) were within the reference
range. There was a negative linear correlation between
lipase activity and creatinine in this dog (r = 0.652,
P = .057). In the second dog with an increased lipase
activity, there was a positive moderate linear correlation
between serum lipase activity and creatinine (r = 0.600,
P = .023). When analyzing the data as a group, there
was minimal and nonsignificant correlation between
serum creatinine concentration and lipase activity in the
5 dogs (r = 0.190, P = .51).
Trypsin-like immunoreactivity was increased in 17 of
50 (34%) samples evaluated (Fig 4). These increases
occurred in 3 dogs. One dog had 1 of 8 TLI values
increased (35.7 lg/L), which occurred when concurrent
serum creatinine concentration was 1.4 mg/dL. A sec-
ond dog had 4 of 11 TLI samples increased; this was
the only dog to show a positive linear correlation
between TLI and serum creatinine concentration
(r = 0.887, P < .001). A third dog had 12 of 14 TLI val-
ues increased, including at baseline. This dog had no
clinical signs of pancreatitis at the beginning or end of
the study. These maximal biomarker increases did not
correlate with the highest creatinine concentration.
When analyzing the data as a group, there was moder-
ate and nonsignificant correlation between serum crea-
tinine and TLI in the 5 dogs (r = 0.458, P = .056).
Recovery from AKI
All 5 dogs recovered from AKI, with final creatinine
concentrations at day 60 ranging from 0.9 to 1.4 mg/dL
(reference range 0.8–1.5 mg/dL), and final USG mea-
surements ranging from 1.022 to 1.039. Spec cPL and
lipase activities were within the normal reference range
in all dogs at the final time point evaluated. One dog
had an increased TLI at the final time point (day 60)
and represented the same dog with an increased TLI at
baseline.
Discussion
This study showed that experimentally induced AKI
did not cause consistent and correlated increases in Spec
cPL, lipase activity, or TLI in dogs. Results also
showed that decreased renal excretion during AKI, as
documented by increases in serum creatinine, did not
affect measurement of these biomarkers in this cohort
Table 1. Correlation coefficients (r) and P-values (Ho:
r=0) for serum creatinine with each biomarker.
Dog(s)
Creat:Spec cPL Creat:Lipase Creat:TLI
r P Value r P Value r P Value
1 0.224 .56 0.761 .02 0.266 .53
2 0.562 .06 0.211 .53 0.887 <.001
3 0.393 .30 0.652 .06 0.706 .03
4 0.704 .01 0.600 .02 0.115 .70
5 0.161 .70 0.528 .18 0.906 .00
All dogs 0.235 .10 0.190 .51 0.458 .06
Creat, serum creatinine concentration; Spec cPL, serum canine
pancreas-specific lipase activity; Lipase, serum lipase activity; TLI,
serum trypsin-like immunoreactivity.
Fig 2. Serum creatinine concentrations and Spec cPL concentrations for each dog (N = 5). Creatinine reference range (0.8–1.5 mg/dL).
Spec cPL reference range (0–200 lg/L). Spec cPL equivocal range (201–399 lg/L) denoted by shaded box.
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of dogs. This finding is similar to previous studies in
dogs with CKD.14,21 Because of the complex metabo-
lism of these pancreatic biomarkers and the possible
effects of extrapancreatic factors on their measurement,
it is important to evaluate them under various disease
conditions, including AKI, so that their use in clinical
practice can be optimized.
A previous study evaluated serum amylase and lipase
activities in dogs with either naturally acquired or surgi-
cally induced CKD.21 Results of that study demon-
strated a 3-fold increase in mean serum lipase activity
in 18 dogs with surgically induced CKD and a 4-fold
increase in mean serum lipase activity in 41 dogs with
naturally occurring CKD; however, these increases were
not correlated with serum creatinine. Another study
evaluated serum lipase activity and serum cPLI in 17
dogs with experimentally induced CKD.14 In that study,
serum lipase activity and cPLI concentrations were
measured at a single time point for each dog and tested
serum samples were stored frozen for approximately
25 years before analysis. No significant increases in
serum lipase activity were found; however, statistically
significant, but not clinically relevant (ie, not outside
the reference range) increases in serum cPLI concentra-
tions were observed.
When evaluating the effects of renal dysfunction on
these biomarkers, it is useful to understand their renal
handling under normal physiologic conditions. Serum
concentrations of these biomarkers are affected by their
generation (ie, prerenal factors, such as pancreatic pro-
duction and enzyme activation) and by both renal and
nonrenal metabolism. Renal handling is affected by
biomarker size and charge (ie, factors affecting permselec-
tivity and glomerular ultrafiltration), and by renal tubular
Fig 3. Serum creatinine concentrations and lipase activities for each dog (N = 5). Creatinine reference range (0.8–1.5 mg/dL). Lipase
activity reference range (138–755 U/L) denoted by the shaded box.
Fig 4. Serum creatinine and TLI concentrations for each dog (N = 5). Creatinine reference range (0.8–1.5 mg/dL). TLI reference range
(5–35 lg/L) denoted by the shaded box.
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handling, (ie, reabsorption). Canine pancreas-specific
lipase (~50,700 MW), trypsinogen (~25,000 MW), and
lipase (~50,000 MW) have a molecular size smaller than
serum albumin, and with regard to glomerular permselec-
tivity are therefore considered to be low molecular
weight molecules. Consequently, the filtration rate and
sieving coefficients of these biomarkers is relatively high.22
A reduction of glomerular filtration in association with
renal dysfunction would therefore be expected to decrease
their relative filtration and increase their serum concentra-
tion. Nevertheless, several studies in dogs with CKD
have not supported this prediction.14,21 In addition to
alterations in filtration, renal tubular damage can lead
to a decrease in tubular uptake of these biomarkers, with
a subsequent increase in their concentration in the
urine.23
In this study, serum biomarkers used currently (Spec
cPL) or historically (lipase and TLI) for the diagnosis of
pancreatitis were evaluated. Although lipase activity and
TLI have poor performance for diagnosis of pancreatitis,
they are still included on common biochemical and gas-
trointestinal panels and their historical use as biomarkers
of pancreatitis prompted their inclusion in this study. In
addition, TLI is used to diagnosis EPI, and the effects of
AKI on this biomarker have not been evaluated. These 3
biomarkers were evaluated at multiple time points and
severities of AKI, during both AKI induction, and recov-
ery from AKI. The spectrum of renal injury achieved in
these dogs spanned International Renal Interest Society
(IRIS) Grades I–IV of AKI, representing a broad range
of disease severity.17 It was possible to correlate changes
in creatinine, as an estimation of GFR, with assessment
of these biomarkers.20
Spec cPL concentrations were increased >400 lg/L in
only 4 of 52 samples (8%), derived from 2 dogs. In con-
trast, AKI was documented in 35 of 52 (67%) samples.
Group analysis revealed a minimal and nonsignificant
correlation between serum creatinine concentration and
Spec cPL. Three of 5 dogs demonstrated no increases in
Spec cPL concentration above the reference range
despite development of AKI, evidenced by maximum
serum creatinine concentrations that were at least dou-
ble the baseline value. The increased serum creatinine
concentrations represent significant kidney dysfunction
and are predictive of significant decreases in GFR.20
The absence of Spec cPL increases in these 3 dogs sug-
gests that acute decreases in renal excretion did not
affect the measurement of serum Spec cPL in dogs with
the grades of AKI achieved in this study. Additionally,
in the 2 dogs with a total of only 4 increased Spec cPL
concentrations, maximum Spec cPL concentrations did
not correlate with maximum creatinine concentrations,
as would be expected if Spec cPL increases were caused
by decreased renal excretion. This finding, combined
with the observation that 3 dogs maintained normal
Spec cPL concentrations throughout the study and the
absence of significant statistical correlation between cre-
atinine and Spec cPL, suggests nonrenal mechanisms
(including the possibility of active pancreatitis) for the
Spec cPL increases in these 2 dogs. In these same 2
dogs, the Spec cPL increases occurred sequentially, fur-
ther supporting that the increases may have been caused
by the transient development of pancreatitis. If mea-
surement of Spec cPL were significantly affected by
decreased renal excretion, all dogs would have been
expected to demonstrate consistent increases in Spec
cPL correlated with the increase in serum creatinine
concentrations. The results of this study demonstrate
that the measurement of Spec cPL is not mechanisti-
cally influenced by acute decreases in kidney function.
This suggests that increases of Spec cPL in dogs with
the degree of AKI achieved in this study could be speci-
fic for pancreatitis, provided that false positive results
are excluded, including other comorbidities that might
affect Spec cPL.
Likewise, the measurement of serum lipase activity
and TLI was not consistently affected by decreased
renal excretion in this cohort of dogs, similar to previ-
ous experimental studies in dogs with CKD.24,25 It
important to note, however, that the correlation
between serum creatinine and TLI in the 5 dogs as a
group, nearly achieved statistical significance at
P = .056, and it is possible that a larger number of dogs
would have led to significant positive correlation
between these variables. Nonetheless, results of this
study demonstrate that the grades of AKI achieved, did
not consistently influence the circulating concentrations
of TLI. It is well documented that trypsin (the active
form of trypsinogen) can bind to inhibitory proteins,
and the large molecular weight of these circulating com-
plexes prevents ultrafiltration by an intact glomerular
membrane.26 In disease states such as renal failure, it is
likely that there are complex physiologic alterations,
including increased reticulendothelial clearance, alter-
ations in glomerular permselectivity and the presence of
trypsin-protease complexes that influence the measured
serum concentration of this biomarker. Studies in
human patients with chronic renal disease have docu-
mented a marked increase in serum trypsinogen concen-
tration relative to healthy controls.27 In addition, the
mean circulating trypsinogen concentration is increased
more frequently and to a higher level than amylase or
lipase in these human patients and this is thought to be
secondary to increased pancreatic release, decreased
renal clearance, or a combination of both; despite this
speculation, a definitive causal relationship between
increased serum trypsinogen and decreased renal clear-
ance has not been made. Differences in size and charge
among amylase, lipase, and trypsinogen did not fully
explain the differences observed in the magnitude of the
increase of these enzymes in humans, and it is highly
plausible that extrarenal clearance mechanisms and net
rates of marker production may be different for each
enzyme.28,29
There were several limitations to this study including
the enrollment of only 5 dogs. Second, pancreatic ultra-
sonography was not performed to evaluate for the pres-
ence of pancreatitis, making it difficult to definitively
explain the causes for the increases in Spec cPL that
occurred in 4 of the 52 serum samples. It is reasonable
to speculate that these observations in 2 dogs repre-
sented either false positive results or the development of
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mild pancreatitis after the experimental procedure and
development of AKI, or the development of AKI. In
addition, it would have been optimal to quantify water
intake in all dogs to more accurately assess for the pres-
ence of hypodipsia.
In conclusion, serum Spec cPL, lipase activity, and
TLI appear to be unaffected by decreased renal excre-
tion in experimental AKI. Additional studies are war-
ranted in a larger cohort of dogs with naturally
occurring AKI.
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